Paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
gemcitabine	gemcitabine	CHEMICALS	O	OTHERS	I
combination	combination	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
within	within	O	O	O	O
a	a	O	O	O	O
multidisciplinary	multidisciplinary	O	O	O	O
therapeutic	therapeutic	O	O	O	O
approach	approach	O	O	O	O
in	in	O	O	O	O
metastatic	metastatic	O	O	O	O
nonsmall	nonsmall	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
lung	lung	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Cisplatin-based	cisplatin-based	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
combinations	combinations	O	O	O	O
improve	improve	O	O	O	O
quality	quality	O	O	O	O
of	of	O	O	O	O
life	life	O	O	O	O
and	and	O	O	O	O
survival	survival	O	O	O	O
in	in	O	O	O	O
advanced	advanced	O	O	O	O
nonsmall	nonsmall	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
lung	lung	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
(	(	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
emergence	emergence	O	O	O	O
of	of	O	O	O	O
new	new	O	O	O	O
active	active	O	O	O	O
drugs	drugs	O	O	O	O
might	might	O	O	O	O
translate	translate	O	O	O	O
into	into	O	O	O	O
more	more	O	O	O	O
effective	effective	O	O	O	O
regimens	regimens	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
disease	disease	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
objective	objective	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
feasibility	feasibility	O	O	O	O
,	,	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
a	a	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
gemcitabine	gemcitabine	CHEMICALS	O	OTHERS	I
combination	combination	O	O	O	O
to	to	O	O	O	O
treat	treat	O	O	O	O
metastatic	metastatic	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Thirty-five	thirty-five	O	O	O	O
consecutive	consecutive	O	O	O	O
chemotherapy-naive	chemotherapy-naive	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
Stage	stage	O	O	O	O
IV	iv	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
and	and	O	O	O	O
an	an	O	O	O	O
Eastern	eastern	O	O	O	O
Cooperative	cooperative	O	O	O	O
Oncology	oncology	O	O	O	O
Group	group	O	O	O	O
performance	performance	O	O	O	O
status	status	O	O	O	O
of	of	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
2	2	O	O	O	O
were	were	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
135	135	O	O	O	O
mg/m(2	mg/m(2	O	O	O	O
)	)	O	O	O	O
given	given	O	O	O	O
intravenously	intravenously	O	O	O	O
in	in	O	O	O	O
3	3	O	O	O	O
hours	hours	O	O	O	O
)	)	O	O	O	O
on	on	O	O	O	O
Day	day	O	O	O	O
1	1	O	O	O	O
,	,	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
120	120	O	O	O	O
mg/m(2	mg/m(2	O	O	O	O
)	)	O	O	O	O
given	given	O	O	O	O
intravenously	intravenously	O	O	O	O
in	in	O	O	O	O
6	6	O	O	O	O
hours	hours	O	O	O	O
)	)	O	O	O	O
on	on	O	O	O	O
Day	day	O	O	O	O
1	1	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
gemcitabine	gemcitabine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
800	800	O	O	O	O
mg/m(2	mg/m(2	O	O	O	O
)	)	O	O	O	O
given	given	O	O	O	O
intravenously	intravenously	O	O	O	O
in	in	O	O	O	O
30	30	O	O	O	O
minutes	minutes	O	O	O	O
)	)	O	O	O	O
on	on	O	O	O	O
Days	days	O	O	O	O
1	1	O	O	O	O
and	and	O	O	O	O
8	8	O	O	O	O
,	,	O	O	O	O
every	every	O	O	O	O
4	4	O	O	O	O
weeks	weeks	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
responding	responding	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
scheduled	scheduled	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
consolidation	consolidation	O	O	O	O
radiotherapy	radiotherapy	O	O	O	O
and	and	O	O	O	O
24	24	O	O	O	O
patients	patients	O	O	O	O
received	received	O	O	O	O
preplanned	preplanned	O	O	O	O
second-line	second-line	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
after	after	O	O	O	O
disease	disease	O	DISEASE	OTHERS	I
progression	progression	O	DISEASE	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
response	response	O	O	O	O
and	and	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
rates	rates	O	O	O	O
reported	reported	O	O	O	O
refer	refer	O	O	O	O
only	only	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
regimen	regimen	O	O	O	O
given	given	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
All	all	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
examined	examined	O	O	O	O
for	for	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
;	;	O	O	O	O
34	34	O	O	O	O
were	were	O	O	O	O
examinable	examinable	O	O	O	O
for	for	O	O	O	O
response	response	O	O	O	O
.	.	O	O	O	O

An	an	O	O	O	O
objective	objective	O	O	O	O
response	response	O	O	O	O
was	was	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
73.5	73.5	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
[	[	O	O	O	O
CI	ci	O	O	O	O
]	]	O	O	O	O
,	,	O	O	O	O
55.6	55.6	O	O	O	O
-	-	O	O	O	O
87.1	87.1	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
4	4	O	O	O	O
complete	complete	O	O	O	O
responses	responses	O	O	O	O
(	(	O	O	O	O
11.7	11.7	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

According	according	O	O	O	O
to	to	O	O	O	O
intention-to-treat	intention-to-treat	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
overall	overall	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
was	was	O	O	O	O
71.4	71.4	O	O	O	O
%	%	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
53	53	O	O	O	O
.	.	O	O	O	O
7	7	O	O	O	O
-	-	O	O	O	O
85.4	85.4	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

After	after	O	O	O	O
154	154	O	O	O	O
courses	courses	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
median	median	O	O	O	O
dose	dose	O	O	O	O
intensity	intensity	O	O	O	O
was	was	O	O	O	O
131	131	O	O	O	O
mg/m(2	mg/m(2	O	O	O	O
)	)	O	O	O	O
for	for	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
97.3	97.3	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
117	117	O	O	O	O
mg/m(2	mg/m(2	O	O	O	O
)	)	O	O	O	O
for	for	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
97.3	97.3	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
1378	1378	O	O	O	O
mg/m(2	mg/m(2	O	O	O	O
)	)	O	O	O	O
for	for	O	O	O	O
gemcitabine	gemcitabine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
86.2	86.2	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

World	world	O	O	O	O
Health	health	O	O	O	O
Organization	organization	O	O	O	O
Grade	grade	O	O	O	O
3	3	O	O	O	O
-	-	O	O	O	O
4	4	O	O	O	O
neutropenia	neutropenia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
in	in	O	O	O	O
39.9	39.9	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
11.4	11.4	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
was	was	O	O	O	O
one	one	O	O	O	O
treatment-related	treatment-related	O	O	O	O
death	death	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Nonhematologic	nonhematologic	O	O	O	O
toxicities	toxicities	O	DISEASE	OTHERS	I
were	were	O	O	O	O
mild	mild	O	O	O	O
.	.	O	O	O	O

After	after	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
follow-up	follow-up	O	O	O	O
of	of	O	O	O	O
22	22	O	O	O	O
months	months	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
median	median	O	O	O	O
progression	progression	O	O	O	O
free	free	O	O	O	O
survival	survival	O	O	O	O
rate	rate	O	O	O	O
was	was	O	O	O	O
7	7	O	O	O	O
months	months	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
median	median	O	O	O	O
survival	survival	O	O	O	O
time	time	O	O	O	O
was	was	O	O	O	O
16	16	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
gemcitabine	gemcitabine	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
and	and	O	O	O	O
shows	shows	O	O	O	O
high	high	O	O	O	O
activity	activity	O	O	O	O
in	in	O	O	O	O
metastatic	metastatic	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
treatment	treatment	O	O	O	O
merits	merits	O	O	O	O
further	further	O	O	O	O
comparison	comparison	O	O	O	O
with	with	O	O	O	O
other	other	O	O	O	O
cisplatin-based	cisplatin-based	O	O	O	O
regimens	regimens	O	O	O	O
.	.	O	O	O	O

